Vaccine trials for SA children
CHINA’S Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, according to Sinovac and its local partner Numolux Group. The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement. The global trial will enrol 14,000 participants across Chile, the Philippines, Malaysia and Kenya, including 2,000 in South Africa, they said. The trial has been approved by South African drugs regulator SAHPRA, and the first child will be vaccinated…